Bone-disease drug could treat breast cancer (Nature News, 29 September 2010)

29 Sep 2010


A collaboration between a group of EU-funded scientists and US-based biotechnology firm Amgen has resulted in two papers published in Nature that implicate RANKL, the target of the new bone drug denosumab, in progestin-driven progression of breast cancer cells.

Full article


Hormones in the News